Ireland - English - HPRA (Health Products Regulatory Authority)

virbac de portugal laboratorios - ivermectin clorsulon - solution for injection - mg/ml - endectoparasiticides - bovine

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. treatment of paget's disease of the bone.,

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. aripiprazole sandoz is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. aripiprazole sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.,

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabine - precursor t-cell lymphoblastic leukemia-lymphoma - antineoplastic agents - nelarabine is indicated for the treatment of patients with t-cell acute lymphoblastic leukaemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,

European Union - English - EMA (European Medicines Agency)

ecuphar - meloxicam - anti inflammatory and antirheumatic products - dogs; cats - oral suspension:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.solution for injection:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.cats:reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - topotecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

virbac s.a. - leishmania infantum excreted secreted proteins - immunologicals - dogs - for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with leishmania infantum.the efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity: 1 year after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psychoanaleptics - dogs - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - hydrocortisone aceponate - corticosteroids, dermatological preparations - dogs - for symptomatic treatment of inflammatory and pruritic dermatoses in dogs.for alleviation of clinical signs associated with atopic dermatitis in dogs.